文献速递垂体与肾上腺疾病

转移性肾上腺皮质癌原发肿瘤减瘤手术对患者生存的影响

Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients' Survival.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

这项多中心回顾性配对队列研究比较了转移性肾上腺皮质癌患者接受原发肿瘤减瘤手术与否的总生存,配对后减瘤组128例、非减瘤组111例,非减瘤组死亡风险高于减瘤组(HR=3.18;95%CI,2.34-4.32),结论认为减瘤手术与生存延长相关。

要点

  • 转移性肾上腺皮质癌原发肿瘤减瘤手术与生存延长相关(HR=3.18;95%CI,2.34-4.32)。
  • 年龄(HR=1.02;95%CI,1.00-1.03)和激素过多(HR=2.56;95%CI,1.66-3.92)为独立预测因素。
  • 局部转移灶治疗与生存相关(HR=0.41;95%CI,0.47-0.65)。

核心结论

  • 转移性肾上腺皮质癌患者的原发肿瘤减瘤手术与生存延长相关。

研究设计与样本

  • 多中心回顾性配对队列研究,数据来自美国-澳大利亚-亚洲肾上腺联盟协作研究组的9个转诊中心。
  • 纳入1995年1月1日至2019年5月31日期间初诊即转移的肾上腺皮质癌患者,年龄≥18岁。
  • 共339例患者汇总,配对后纳入239例:减瘤组128例,非减瘤组111例。
  • 采用倾向性评分匹配,匹配变量为年龄和转移器官数目(≤2或>2)。
  • 主要结局为总生存,从诊断日期算至死亡或存活患者末次随访。

主要发现

  • 平均随访67个月。
  • 非减瘤组死亡风险高于减瘤组(HR=3.18;95%CI,2.34-4.32)。
  • 年龄为独立预测因素(HR=1.02;95%CI,1.00-1.03)。
  • 激素过多为独立预测因素(HR=2.56;95%CI,1.66-3.92)。
  • 局部转移灶治疗为独立预测因素(HR=0.41;95%CI,0.47-0.65)。

临床怎么用

  • 原文结论认为转移性肾上腺皮质癌原发肿瘤减瘤手术与生存延长相关。
  • 原文未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The role of cytoreduction of adrenocortical carcinoma (ACC) remains poorly understood. OBJECTIVE: To analyze the impact of cytoreductive surgery of the primary tumor in patients with metastatic ACC. DESIGN AND SETTING: We performed a multicentric, retrospective paired cohort study comparing the overall survival (OS) in patients with metastatic ACC who were treated either with cytoreductive surgery (CR group) or without cytoreductive surgery (no-CR group) of the primary tumor. Data were retrieved from 9 referral centers in the American-Australian-Asian Adrenal Alliance collaborative research group. PATIENTS: Patients aged ≥18 years with metastatic ACC at initial presentation who were treated between January 1, 1995, and May 31, 2019. INTERVENTION: Performance (or not) of cytoreductive surgery of the primary tumor. MAIN OUTCOME AND MEASURES: A propensity score match was done using age and the number of organs with metastasis (≤2 or >2). The main outcome was OS, determined from the date of diagnosis until death or until last follow-up for living patients. RESULTS: Of 339 patients pooled, 239 were paired and included: 128 in the CR group and 111 in the no-CR group. The mean follow-up was 67 months. Patients in the no-CR group had greater risk of death than did patients in the CR group (hazard ratio [HR] = 3.18; 95% CI, 2.34-4.32). Independent predictors of survival included age (HR = 1.02; 95% CI, 1.00-1.03), hormone excess (HR = 2.56; 95% CI, 1.66-3.92), and local metastasis therapy (HR = 0.41; 95% CI, 0.47-0.65). CONCLUSION: Cytoreductive surgery of the primary tumor in patients with metastatic ACC is associated with prolonged survival.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Srougi V, Bancos I, Daher M, et al. Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients' Survival. J Clin Endocrinol Metab. 2022. PMID: 34850915. doi:10.1210/clinem/dgab865

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。